Phase I and II studies in adults with relapsed/refractory CD30+lymphomas, including ALCL, demonstrated the safety and efficacy of brentuximab vedotin, leading to FDA approval for relapsed/refractory ALCL in adults and successful incorporation into frontline therapies61. Here, TNFRSF8 is linked to lymphoma.